Pfizer (PFE) – Get Free Report shares slumped lower in pre-market trading after the drugmaker slashed its full-year sales and profits forecasts, while unveiling steep job cuts, linked to slowing demand for its Covid vaccines and treatments.
In a late Friday update that precedes a group conference call with analysts later today, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its Comirnaty covid vaccine and its Paxlovid antiviral treatment.
In response, Pfizer said it would write-off around $4.6 billion in Paxlovid inventories, while taking a further $5.5 billion non-cash charge against its third quarter earnings. It also unveiled plans for a $3.5 billion cost-cutting program, spread over two years, that will include a significant number of job cuts.
Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share.
“Pfizer’s non-COVID product portfolio remains strong, and we continue to expect these products to achieve year-over-year operational revenue growth in the range of 6% to 8% in 2023,” said CEO Albert Bourla.
“We remain proud that our scientific breakthroughs played a significant role in getting the global health crisis under control,” he added. “We continue to expect our COVID-related revenues to contribute to our business in future periods, helping us to further invest in activities that drive Pfizer’s long-term growth potential.”
Pfizer shares were marked 3.3% lower in pre-market trading to indicate an opening bell price of $31.06 per share.
Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
